terfenadine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
2600 50679-08-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • terfenadine
  • ternadin
  • racemic terfenadine
  • seldane
A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME.
  • Molecular weight: 471.69
  • Formula: C32H41NO2
  • CLOGP: 6.07
  • LIPINSKI: 1
  • HAC: 3
  • HDO: 2
  • TPSA: 43.70
  • ALOGS: -6.01
  • ROTB: 9

Drug dosage:

DoseUnitRoute
0.12 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 4.24 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 1 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 4.347 High 0.81
caco2-efflux Caco-2 efflux ratio (BA/AB) 7.816 High 0.81
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 1.977 10^-6 cm/s High 0.81
dh-clint Dog hepatocyte intrinsic clearance 21.038 uL/min/10^6 cells High 0.81
dppb Dog plasma protein binding (% unbound) 0.640 % High 0.81
fcs-ppb Fetal calf serum protein binding (% unbound) 2.870 % High 0.81
herg hERG pIC50 5.887 pIC50 High 0.81
hh-clint Human hepatocyte intrinsic clearance 24.378 uL/min/10^6 cells High 0.81
hlm-clint Human liver microsomal intrinsic clearance 115.611 uL/min/mg protein High 0.81
hppb Human plasma protein binding (% unbound) 0.760 % High 0.81
kinase-safety-class ACVR2A,ACVR2B,AKT1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,MAP3K21,MAP3K7,MAPK10,MAPK12,MAPK7,MET,MTOR,NTRK2,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,TEK,TGFBR1,TTK 46
kinase-selectivity-class AXL,BRAF,EPHB4,GRK2,PDK4 5
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 0.582 High 0.81
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 6.607 High 0.81
mh-clint Mouse hepatocyte intrinsic clearance 62.230 High 0.81
mppb Mouse plasma protein binding (% unbound) 0.580 High 0.81
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 29.040 High 0.81
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 High 1
pppb Pig plasma protein binding (% unbound) 2.180 % High 0.81
rat-kpuu-brain Rat brain Kpuu 0.199 % High 0.81
rh-clint Rat hepatocyte intrinsic clearance 82.224 uL/min/10^6 cells High 0.81
rh-fuinc Rat hepatocyte fraction unbound in incubation 1.400 % High 0.81
rppb Rat plasma protein binding (% unbound) 0.610 % High 0.81
solubility-dd Solubility at pH 7.4 in DMSO 12.764 uM High 0.81

Approvals:

DateAgencyCompanyOrphan
None FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 102.37 73.70 23 9 463586 90164829

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC R06AX12 RESPIRATORY SYSTEM
ANTIHISTAMINES FOR SYSTEMIC USE
ANTIHISTAMINES FOR SYSTEMIC USE
Other antihistamines for systemic use
MeSH PA D006633 Histamine Antagonists
MeSH PA D006634 Histamine H1 Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D039563 Histamine H1 Antagonists, Non-Sedating
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35705 immunosuppressive agent
CHEBI has role CHEBI:64951 anti-HBV agent
CHEBI has role CHEBI:65023 anti-asthmatic agent

Related Drugs by ATC class:

R06AX Other antihistamines for systemic use 26 drugs
acrivastineantazolineastemizoleazatadineazelastinebamipinebilastinecyproheptadinedeptropinedesloratadineebastineepinastine show all 26 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Vasomotor rhinitis indication 8229003 DOID:4730
Allergic rhinitis indication 61582004
Nasal discharge indication 64531003
Nasal congestion indication 68235000
Sneezing indication 76067001
Common cold indication 82272006 DOID:10459
Chronic idiopathic urticaria indication 302162004
Seasonal allergic rhinitis indication 367498001
Allergic conjunctivitis indication 473460002 DOID:11204
Urticaria off-label use 126485001
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Coronary arteriosclerosis contraindication 53741008 DOID:3393
Diabetes mellitus contraindication 73211009 DOID:9351
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Angle-closure glaucoma contraindication 392291006 DOID:13550
Hypertensive urgency contraindication 443482000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.85 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Histamine H1 receptor GPCR ANTAGONIST Ki 8.70 WOMBAT-PK IUPHAR
D(2) dopamine receptor GPCR Ki 5.69 DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 7.25 WOMBAT-PK
Multidrug resistance protein 1 Transporter IC50 5.85 WOMBAT-PK
Sodium-dependent noradrenaline transporter Transporter Ki 5.72 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 7.14 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 7.52 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 6.19 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 6.22 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 6.29 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR IC50 5.54 CHEMBL
Alpha-2C adrenergic receptor GPCR Ki 6.26 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 6.69 DRUG MATRIX
Epidermal growth factor receptor Kinase IC50 5.45 DRUG MATRIX
C-C chemokine receptor type 5 GPCR Ki 6.07 DRUG MATRIX
Tyrosine-protein kinase Fyn Kinase IC50 5.21 DRUG MATRIX
Cytochrome P450 2J2 Enzyme IC50 5.09 CHEMBL
Substance-K receptor GPCR Ki 6.05 DRUG MATRIX
Potassium voltage-gated channel subfamily H member 1 Ion channel BLOCKER IC50 7.80 IUPHAR
Heat shock protein HSP 90-alpha Cytosolic other IC50 5.46 WOMBAT-PK
Adrenergic receptor alpha-1 GPCR IC50 5.63 CHEMBL
D(1A) dopamine receptor GPCR Ki 5.87 DRUG MATRIX
Alpha-1B adrenergic receptor GPCR Ki 5.73 DRUG MATRIX
Histamine H1 receptor GPCR Kd 7.45 CHEMBL
Transcriptional activator protein luxR Transcription factor IC50 4.04 CHEMBL

External reference:

IDSource
4019295 VUID
N0000147493 NUI
D00521 KEGG_DRUG
4019295 VANDF
C0085173 UMLSCUI
CHEBI:9453 CHEBI
CHEMBL17157 ChEMBL_ID
D016593 MESH_DESCRIPTOR_UI
DB00342 DRUGBANK_ID
2608 IUPHAR_LIGAND_ID
3674 INN_ID
7BA5G9Y06Q UNII
5405 PUBCHEM_CID
202960 RXNORM
1520 MMSL
2365 MMSL
5550 MMSL
d00387 MMSL
003412 NDDF
16037009 SNOMEDCT_US
387089004 SNOMEDCT_US
7BA5G9Y06Q INXIGHT DRUGS

Pharmaceutical products:

None